Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2024 | $28.00 | Outperform | Robert W. Baird |
| 6/6/2024 | $22.00 | Buy | H.C. Wainwright |
| 11/28/2023 | $20.00 | Overweight | JP Morgan |
| 11/28/2023 | $20.00 | Buy | Stifel |
| 11/28/2023 | $19.00 | Outperform | Leerink Partners |
| 11/28/2023 | $22.00 | Outperform | RBC Capital Mkts |
| 11/28/2023 | $23.00 | Buy | Chardan Capital Markets |
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N
Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00
H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00
JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $22 price target.
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)